Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients

Recent Results Cancer Res. 1993:131:207-14. doi: 10.1007/978-3-642-84895-7_18.

Authors

R Foa¹, G Meloni, A Guarini, M Vignetti, D Marchis, S Tosti, A Gillio Tos, F Mandelli, F Gavosto

Affiliation

¹ Dipartimento di Scienze Biomediche e Oncologia Umana, University of Turin, Italy.

PMID: 8210640
DOI: 10.1007/978-3-642-84895-7_18

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Animals
Humans
Immunotherapy
Interleukin-2 / therapeutic use*
Killer Cells, Lymphokine-Activated / immunology
Leukemia / therapy*
Mice
Recombinant Proteins / therapeutic use

Substances

Interleukin-2
Recombinant Proteins